This study aims to better understand people who have advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation. NSCLC is an advanced stage cancer of the lung, occurring due to mutations (changes) in the EGFR gene. The study will assess the participant demographic background (that is age, gender etc.), the treatments they receive, how well those treatments work, and their health outcomes.
Study Type
OBSERVATIONAL
Enrollment
250
Sociodemographic Characteristics: Age
Age in years of the participants will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Sex
Sex (male, female) of the participants will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Weight
Weight (in kilograms \[kg\]) of the participants will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Smoking Status
Participants smoking status that is current or former smoker will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Eastern Cooperative Oncology Group (ECOG) Performance Status
ECOG performance status of the participants will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Disease Histopathology
Number of participants based on disease histopathology will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Type of Mutation
Number of participants based on type of mutation will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Disease Stage
Number of participants based on the stage of disease will be reported.
Time frame: Baseline
Sociodemographic Characteristics: Cancer Metastasis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of participants based on cancer metastasis will be reported.
Time frame: Baseline
EGFR Mutation Prevalence
Number of participants with EGFR mutations will be reported.
Time frame: Up to approximately 7 years 9 months
Percentage of Participants by Type of Mutation of EGFR
Percentage of participants by type of mutation of EGFR will be reported.
Time frame: Up to approximately 7 years 9 months
Frequency of EGFR Mutations
Frequency of EGFR mutations will be reported.
Time frame: Up to approximately 7 years 9 months
Number of Participants by Treatment Options
Participants with different treatment options such as targeted therapy, chemotherapy, immunotherapy, surgery, radiotherapy stratified by type of mutation will be reported.
Time frame: Up to approximately 7 years 9 months
Real-World Overall Survival (RW-OS)
RW-OS is defined as time elapsed between index date and date of death from any cause.
Time frame: Up to approximately 7 years 9 months
Real-World Progression-Free Survival (RW-PFS)
RW-PFS is defined as the time elapsed between the start of a new line of treatment to the date of documented disease progression or death from any cause, whichever occurs first.
Time frame: Up to approximately 7 years 9 months
RW-PFS from First Line of Treatment (RW-PFS 2)
RW-PFS 2 is defined as the time elapsed between the start of a first line of treatment to the date of documented second disease progression or death from any cause, whichever occurs first.
Time frame: Up to approximately 7 years 9 months
Real-World Time on Treatment (RW-TOT)
RW-TOT is defined as the time elapsed between the start date of a line of treatment to the date of treatment discontinuation for any reason.
Time frame: Up to approximately 7 years 9 months
Real-World Time to Next Treatment (RW-TTNT)
RW-TTNT is defined as the time elapsed between the start of a given line of treatment to the initiation of the subsequent line of systemic therapy.
Time frame: Up to approximately 7 years 9 months
Real-World Overall Response Rate (RW-ORR)
RW-ORR is defined as the percentage of participants whose cancer show partial response or complete response of all target lesions following a specific line of treatment.
Time frame: Up to approximately 7 years 9 months
Number of Appointments
Number of appointments related to NSCLC by line of treatment such as oncology, pulmonology, primary care, radio-oncology, thoracic surgery, nursing, psychology, nutrition, physiotherapy will be reported.
Time frame: Up to approximately 7 years 9 months
Number of Participants Receiving Complementary Diagnostic and Therapeutic Procedures
Number of participants receiving complementary diagnostic and therapeutic procedures and type of complementary diagnostic and therapeutic procedures received (for example, imaging, laboratory tests, biopsies, radiotherapy sessions, surgery, medication) will be reported.
Time frame: Up to approximately 7 years 9 months
Number Participants with Emergency Room Visits Related to NSCLC
Number of participants with emergency room visits related to NSCLC will be reported.
Time frame: Up to approximately 7 years 9 months
Percentage of Participants Hospitalized
Percentage of participants with at least one hospitalization will be reported.
Time frame: Up to approximately 7 years 9 months
Number of Hospitalizations
Total number of hospitalizations for the participants will be reported.
Time frame: Up to approximately 7 years 9 months
Median Length of Stay
Median length of stay in days per hospitalization will be reported.
Time frame: Up to approximately 7 years 9 months
Net Costing
The net cost of different treatment practices per participants will be reported.
Time frame: Up to approximately 7 years 9 months